qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

NCT ID: NCT02466828

Last Updated: 2018-04-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2018-04-30

Brief Summary

Glioblastoma multiforme (GBM) is the most common primary malignant brain neoplasm in adults. Despite recent diagnostic and therapeutic advances, including aggressive surgical resection and chemoradiation, the prognosis of GBM has improved only slightly over the past two decades, with median survival of approximately 15 months. Tumor hypoxia is a feature of GBM that contributes to poor outcome through multiple mechanisms such as 1) overexpression of enzymes that play roles in temozolomide resistance, the main chemotherapeutic agent in GBM and 2) increase expression of cancer stem cells which are more resistant to radiation. Hypoxic tumour regions are associated with higher rates of progression and recurrence.

In this study the investigators will use an advanced MRI technique called qBOLD to non-invasively measure oxygenation in GBM and obtain targeted biopsies. The investigators take advantage of physical characteristics of Ferumoxytol (Feraheme®) which is an iron supplement, and utilize two recent technical advances not previously used in human tumours to quantitatively measure oxygenation in GBM.

Prior knowledge of hypoxia can assist in prognostication and individualization of treatment planning with special focus on hypoxic regions by targeted radiation dose or regimen modulation; consideration of more intensive chemotherapy regimens; more aggressive and targeted surgical resection and closer short-term clinical and imaging follow-ups.

Detailed Description

We propose a study to demonstrate quantitative oxygen saturation estimation in GBM is feasible with qBOLD and it correlates with established histopathological markers of hypoxia and angiogenesis, and targeted intraoperative oxygen measurement.

All patients will undergo surgery as part of their standard treatment. By coregistering the hypoxia map on presurgical MRI we will be able to do the following:

1. Obtain targeted biopsies of the hypoxic areas and none hypoxic areas and correlate them with gold standard marker of tissue hypoxia by immunohistochemistry for hypoxia induced factor-1α (HIF-1α).

2. Draw Volumes of interests (VOI) over areas >0.5-cm3 (amenable to accurate intra-operative O2 measurement) with the lowest and highest oxygen saturation (SO2) values. VOIs will be then imported into the neuronavigation system (Stryker) for targeted placement of clinically approved Licox® oxygen-sensing probe (Integra NeuroSciences).

Conditions

Glioblastoma; Hypoxia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Single patient group receiving Feraheme®

Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent

Group Type: EXPERIMENTAL

Feraheme®

Intervention Type: DRUG

Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.

Interventions

Feraheme®

Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.

Intervention Type: DRUG

Other Intervention Names

ferumoxytol

Eligibility Criteria

Inclusion Criteria

1. Adult (>18 year old) patients with newly diagnosed GBM presenting to our centre for surgical management and post-operative chemoradiation

2. Creatinine clearance > 60 ml/minute

3. Able to tolerate an MR scan

4. Capable of providing informed consent.

Exclusion Criteria

1. Prior brain surgery or radiation

2. History of liver disease requiring liver MRI (due to accumulation of ferumoxytol in Kupffer cells which can affect liver MRI for up to 3 months)

3. On more than two antihypertensive medications

4. History of allergy or adverse reaction to iron supplements

5. Prior treatment with ferumoxytol

6. Large (>50%) hemorrhagic component in the solid enhancing part of the tumor

7. Need for emergency craniotomy.

8. Pregnant patients

9. Breast feeding

10. Serum ferritin of >800 ng/mL

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Unity Health Toronto

OTHER

Sponsor Role: collaborator

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pejman Jabehdar Maralani, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Center

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

St. Michael's Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

127-2014

Identifier Type: -

Identifier Source: org_study_id